SUPN FY 2025 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

FY 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$719M+8.6% YoY

Gross Profit

$644M89.6% margin

Operating Income

-$37M-5.1% margin

Net Income

-$39M-5.4% margin

EPS (Diluted)

$-0.68

Cash Flow

Operating Cash Flow

$47M

Free Cash Flow

$46M

Stock-Based Comp.

$33M

Balance Sheet

Total Assets

$1.5T

Total Liabilities

$390.9B

Stockholders' Equity

$1.1T

Cash & Equivalents

$128.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$719M	$662M	+8.6%
Gross Profit	$644M	$584M	+10.4%
Operating Income	-$37M	$82M	-145.1%
Net Income	-$39M	$74M	-152.2%